Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates

Core Insights - Apellis Pharmaceuticals, Inc. reported quarterly earnings of $1.67 per share, exceeding the Zacks Consensus Estimate of $1.03 per share, and showing a significant improvement from a loss of $0.46 per share a year ago, resulting in an earnings surprise of +62.14% [1] - The company achieved revenues of $458.58 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 25.22%, compared to revenues of $196.83 million in the same quarter last year [2] - The stock has underperformed the market, losing about 5.8% since the beginning of the year, while the S&P 500 has gained 17.2% [3] Earnings Outlook - The future performance of Apellis Pharmaceuticals' stock will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $201.39 million, and for the current fiscal year, it is -$0.30 on revenues of $913.09 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Apellis Pharmaceuticals belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]